Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra BioMed’s future revenue as well as equity Funding supports continued execution of Orchestra BioMed’s pivotal trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results